Table 2.

Comparison of studies on the treatment of CNV secondary to PIC.

	Coco et al. [15]	Peng et al. [12]	Fong et al. [6]	Menezo et al. [11]	Zhang et al. [8]	Our study
Study design	Retrospective	Prospective	Prospective	Retrospective	Prospective	Retrospective
No. of eyes	8	16	5	10	12	24
Treatment	vPDT	Conbercept	vPDT+ Corticosteroid	Ranibizumab	Bevacizumab	Ranibizumab +/- Corticosteroid
Initial BCVA (logMAR)	0.42	0.70	0.54	0.72	0.49	Ranibizumab: 0.68; Ranibizumab+ Corticosteroid: 0.82
Final BCVA (logMAR)	0.51	0.44	0.39	0.37	0.23	Ranibizumab: 0.34; Ranibizumab+ Corticosteroid: 0.22
Mean follow-up (months)	22.7	6	12	12.5	12	Ranibizumab: 23.3; Ranibizumab+ Corticosteroid: 24.5
Improved or stable BCVA (eyes)	5 (62.5%)	16 (100%)	4 (80%)	9 (90%)	12 (100%)	Ranibizumab: 13 (92.9%); Ranibizumab+ Corticosteroid: 10 (100%)

Improved or stable BCVA means that BCVA of the patient kept stable (less than 0.1 in change) or was improved to more than 0.1 after the treatment.